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 Activation of hemostatic pathways by blood-contacting materials remains 
a major hurdle in the development of clinically durable artifi cial organs and 
implantable devices. Here, it is postulated that surface-induced thrombosis 
may be attenuated by the reconstitution onto blood contacting surfaces 
of bioactive enzymes that regulate the production of thrombin, a central 
mediator of both coagulation and platelet activation cascades. Thrombo-
modulin (TM), a transmembrane protein expressed by endothelial cells, 
is an established negative regulator of thrombin generation in the circula-
tory system. Traditional techniques to covalently immobilize enzymes on 
solid supports may modify residues contained within or near the catalytic 
site, thus reducing the bioactivity of surface enzyme assemblies. In this 
report, a molecular engineering and bioorthogonal chemistry approach to 
site-specifi cally immobilize a biologically active recombinant human TM 
fragment onto the luminal surface of small diameter prosthetic vascular 
grafts is presented. Bioactivity and biostability of TM modifi ed grafts is 
confi rmed in vitro and the capacity of modifi ed grafts to reduce platelet 
activation is demo nstrated using a non-human primate model. These 
studies indicate that mole cularly engineered interfaces that display TM 
actively limit surface-induced thrombus formation. 
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 The molecular engineering of biologically 
active surface assemblies that control host 
reactions at tissue-material interfaces may 
be an important step in the development 
of clinically durable artifi cial organs and 
implantable devices. [ 1 , 2 ] In this regard, 
pathological thrombus formation on mate-
rials in direct contact with blood has pre-
cluded development of a clinically durable 
small-diameter ( < 5 mm inner diameter) 
arterial prosthesis critical to the fi elds of 
cardiac, vascular, and plastic surgery, and 
has necessitated adjunctive antithrom-
botic therapies that increase bleeding 
risk and healthcare costs for numerous 
cardiovascular procedures. [ 3 , 4 ] The onset 
and amplifi cation of thrombogenesis 
on blood-contacting materials involves 
concomitant activation of platelets and 
elaboration of the coagulation cascade to 
generate thrombin and fi brin, culminating 
in hemostatic plug formation. [ 5 ] Thrombin 
serves as a central initiator, amplifi er, and 
effector molecule at the nexus of these pathways by crosslinking fi brin, directly triggering platelet 
activation that leads to a local burst of thrombin production, [ 6 ] 
and eliciting infl ammatory reactions [ 7 ] that infl uence long-term 
healing characteristics of implanted materials. [ 8 ] Therefore, a 
rational approach to improve blood compatibility and long-term 
durability of blood-contacting materials may entail the incor-
poration of endogenous regulators of thrombin production, 
normally active within the endothelial cell membrane, onto 
synthetic molecularly engineered surfaces. 
 Heparan sulfate proteoglycans (HSPG) in the arterial wall 
accelerates thrombin inactivation by antithrombin III, a mecha-
nism Gott and coworkers fi rst replicated on artifi cial surfaces 
by heparin immobilization in 1963. [ 9 ] However, the physiolog-
ical signifi cance of HSPG remains poorly understood, since the 
majority of anticoagulantly active HSPG is not in direct contact 
with fl owing blood, [ 10 ] and thrombin becomes resistant to inhi-
bition by the heparin-antithrombin III complex upon binding 
to fi brin. [ 11 ] Alternatively, surface-bound direct thrombin inhibi-
tors, such as hirudin [ 12–15 ] and its analogues, [ 16 ] as well as arga-
troban, [ 17 , 18 ] and benzamidine [ 19 ] quench the activity of locally im Adv. Funct. Mater. 2011, 21, 4736–4743
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 Scheme  1 .  Reaction sequence to covalently immobilize recombinant human thrombomodulin (TM) onto the luminal surface of expanded 
poly(tetrafl uoroethylene) (ePTFE) grafts: (1) generation of polyurethane (PU) coating on ePTFE graft lumen; (2) isocyanate activation of PU with 
hexamethylene diisocyanate; (3) immobilization of amino-PEG 11 -triphenylphosphine (NH 2 –PEG 11 –TPP) linker; (4) Staudinger Ligation of recombinant 
TM expressing a single C-terminal azide moiety (TM-N 3 ) to TPP. produced thrombin. However, a potential constraint of these 
approaches is the inability to generate a continuous surface res-
ervoir of direct thrombin inhibitors that would be required to 
curtail self-reinforcing thrombin generation cascades which are 
rapidly amplifi ed upon initiation. Hemostatic occlusion in the 
arterial circulation is actively regulated by the protein C (PC) 
pathway, whereby activated protein C (aPC) inactivates precur-
sors requisite for amplifi cation of coagulation and thrombin 
formation. [ 20 ] Endothelial cells that line the vascular system 
express thrombomodulin (TM), a transmembrane protein 
that binds thrombin as a 1:1 stoichiometric complex. In the 
process of sequestering thrombin, TM limits its capacity to acti-
vate platelets or to otherwise serve as a prothrombotic factor. 
More importantly, TM accelerates thrombin’s ability to produce 
aPC by 1000-fold. [ 21 ] Hence, we postulate that engineering 
blood-contacting surfaces which display biologically active TM 
assemblies would locally generate aPC “on demand”, thereby, 
inhibiting thrombin generation. 
 Traditional techniques to immobilize active enzymes on 
solid supports, such as passive adsorption or covalent ligation 
via free amino or carboxyl residues [ 22 ] have been reported to 
generate surfaces modifi ed with TM. [ 23–30 ] However, these cova-
lent ligation approaches randomly orient immobilized enzymes 
and potentially modify residues contained within or near the 
catalytic site, [ 31 ] consequently reducing optimal surface activity 
that could otherwise be achieved by these enzyme assemblies. 
Emerging advances in bioorthogonal chemistry and molecular 
engineering provide an opportunity to site-specifi cally tether 
large enzymes onto surfaces. The azide (-N 3 ) group is absent 
from biological systems and was fi rst explored as a bioortho-
gonal handle with Staudinger Ligation. [ 32 ] Further application 
of this chemistry to immobilize proteins containing an azide-
modifi ed C terminus has been performed on glass surfaces 
modifi ed with triphenylphosphine, [ 33 , 34 ] but thiol reagents used 
in expressed protein ligation to generate the azide moiety may 
perturb the folding and catalytic activity of bioenzymes rich in 
disulfi de bonds, [ 35 ] including TM. [ 36 ] An alternative strategy that 
fi rst converted a single lysine residue to azide facilitated immo-
bilization of an active enzyme by traceless Staudinger Ligation 
on glass, which maximized its bioactivity relative to random 
coupling via amine residues. [ 37 ] However, a possible limitation 
of this approach is the lack of site-specifi city when multiple 
lysines are present in larger biomolecules, such as TM. 
 Our laboratory has generated a truncated 15 kDa human 
TM fragment containing the soluble extracellular epidermal © 2011 WILEY-VCH Verlag GmAdv. Funct. Mater. 2011, 21, 4736–4743growth factor-like domains 4 through 6 (EGF 4-6 ), [ 38 ] which dis-
plays the requisite binding sites for thrombin and protein C 
necessary to catalyze production of aPC. [ 39 ] Using site-specifi c 
incorporation of the non-canonical methionine surrogate azi-
dohomoalanine, [ 40 ] we have generated a TM variant expressing 
a single C-terminal azide moiety (TM-N 3 ). In this report, 
we immobilize recombinant TM-N 3 by Staudinger Ligation 
onto the luminal surface of polyurethane coated expanded 
poly(tetrafl uoroethylene) (ePTFE) vascular grafts ( Scheme  1 ). 
Further, we demonstrate the capacity of these surfaces to gen-
erate aPC and confi rm the stability of TM surface assemblies 
in vitro. The ability of TM modifi ed grafts to inhibit throm-
bosis in vivo was demonstrated using a non-human primate 
model. 
 2. Results and Discussion 
 2.1. Coating of ePTFE Grafts with a Polyurethane Film 
 Although inert PTFE surfaces may be modifi ed by high energy 
radiation to generate reactive chemical handles, [ 41 ] translation 
of these techniques to ePTFE vascular prostheses on clini-
cally relevant length scales has been diffi cult. Therefore, an 
extrusion method was used to deposit a thin coating of med-
ical grade Elasthane 80A polyurethane (PU) onto the luminal 
surface of ePTFE grafts that could then be readily modifi ed 
by chemical techniques. [ 42 ] Scanning electron microscopy 
(SEM) confi rmed deposition of a smooth, uniform  ∼ 50  μ m 
PU fi lm that penetrated the porous node-fi bril architecture of 
ePTFE  ( Figure  1 ) . As expected, PU coating thickness was pro-
portional to the quantity of material deposited and uniform 
along the length of the prosthesis ( Figure  2 ). Attenuated total 
refl ectance IR (ATR-IR) spectroscopy was performed on PU 
coatings on ePTFE ( Figure  3 a ), as well as model thin fi lms 
generated by solvent casting of PU onto glass substrates 
(Figure  3 b). Characteristic of PU a hydrogen-bonded ure-
thane N–H peak at 3320 cm  − 1 was observed, as were peaks at 
2885 and 1535 cm  − 1 corresponding to C–H stretching and 
C–H–N bending, respectively. Additional PU peaks were 
detected at 1591 cm  − 1 (C = C, aromatic ring), 1110 cm  − 1 
(C–O–C, stretch), 1730 cm  − 1 (urethane C = O, free from 
hydrogen bonding), and 1710 cm  − 1 (urethane C = O, hydrogen 
bonded), consistent with prior reports. [ 43 ] bH & Co. KGaA, Weinheim 4737wileyonlinelibrary.com
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 Figure  1 .  Scanning electron microscopy of polyurethane (PU) coating on (a) the edge of ePTFE graft at 100 × , and on (b) the luminal surface at 100 × 
and (c) 2000 × . Scale bars: a,b) 100  μ m; (c) 5  μ m. 
 Figure  2 .  Light microscopy of thin cross sections of polyurethane (PU) 
coated ePTFE grafts. (a) Interface between opaque ePTFE graft wall and 
transparent 2-layer PU lining observed at 4 × . (b) Mean  ± standard devia-
tion of PU thickness measured at 4 positions per cross section and 1 cm 
intervals along 8 cm ePTFE graft segment coated with 2, 3, and 4 depos-
ited layers of PU on top of a base extruded layer. (c) Interface between 
opaque ePTFE graft wall and transparent 4 layer PU lining observed at 
20 × . Scale bars: (a) 500  μ m; (c) 100  μ m.  2.2. Chemical Modifi cation of ePTFE Grafts 
 Amine-reactive isocyanate groups were generated on PU coated 
grafts using a rotary reactor, which facilitated uniform mixing of © 2011 WILEY-VCH Verlag G38 wileyonlinelibrary.com
 Figure  3 .  Attenuated refl ection infrared spectroscopy of (a) polyurethane (P
PU fi lms. Representative spectra given for (i) PU, (ii) PU subjected to isoc
with a heterobifunctional NH 2 -PEG 11 -triphenylphosphine linker. reagents ( Figure  4 ). [ 44 ] PU coated grafts were incubated for 1 h with 
hexamethylene diisocyanate (HDI) in the presence of triethylamine 
(TEA) at 50  ° C, as demonstrated elsewhere. [ 45 ] ATR-IR spectroscopy 
detected a distinct peak at 2260 cm  − 1 corresponding to –N = C = O 
(Figure  3 ). A heterobifunctional linker comprised of a poly(ethylene 
glycol) (PEG) spacer with amino (–NH 2 ) and triphenylphosphine 
(TPP) end groups (NH 2 –PEG 11 –TPP) was used to derivatize acces-
sible surface isocyanates (Scheme  1 ), as confi rmed by loss of the 
–N = C = O peak by ATR spectroscopy (Figure  3 ). Consistent with 
this fi nding, X-ray photoelectron spectroscopy (XPS) revealed a 
sharp decrease in the C (285 eV) to O (532 eV) ratio ( Figure  5 a–c 
and  Table  1 ) and the presence of distinct phosphorous peaks (P 2p 
at 133 eV and P 2s at 200 eV) (Figure  5 c). The absence of fl uo-
rine peaks (Figure  5 a–c) further confi rmed complete coverage of 
ePTFE by the PU thin fi lm. High resolution C 1 s XPS (Figure  5 d–f 
and Table  1 ) revealed a dramatic increase in N–C = O (289.0 eV) 
intensity and increased ether carbon content (C–O, 286.4 eV) after 
immobilization of the PEG linker. These observations confi rm the 
initial generation of reactive isocyanates followed by the display of 
TPP moieties on the luminal surface of PU-coated ePTFE grafts. 
 2.3. Staudinger Ligation of Azide Probe on ePTFE 
 A fl uorescent azide probe was used to initially assess the specifi -
city of small molecule immobilization by Staudinger Ligation. [ 46 ] mbH & Co. KGaA, Weinheim Adv. Funct. Mater. 2011, 21, 4736–4743
U) coated on the luminal surface of ePTFE grafts and (b) thin solvent cast 
yanate activation with hexamethylene diisocyanate, and (iii) PU modifi ed 
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 Figure  4 .  Reactor setup for chemical derivatization of PU modifi ed ePTFE grafts. (a) 4 mm i.d. ePTFE grafts were chemically modifi ed using a custom 
reactor design comprising (i) reactor housing for ePTFE graft and a (ii) DC motor that is coupled to a (iii) form-fi tting rotator clamp for graft reac-
tors to facilitate rotation along the axial length of grafts. (b) Inner construction of reactor housing for ePTFE graft comprising (i) barbed Kynar plugs 
to seal both ends of tubular reaction vessel; (ii) inner 5 mm i.d., 7 mm o.d. Tefl on tube; (iii) 4 mm i.d. ePTFE graft; (iv) outer 7 mm i.d., 9 mm o.d. 
Tefl on tube. Rhodamine B and its azide analogue tetramethylrhodamine 
5-carbonyl azide (Rh-N 3 ) were reacted in parallel with PU fi lms 
functionalized with TPP. Following extensive rinsing in meth-
anol, it was evident that only Rh-N 3 was covalently immobilized 
to TPP modifi ed PU fi lms ( Figure  6 a ). This result was semi-
quantitatively corroborated by UV-Vis spectroscopy (Figure  6 b), 
and verifi ed visually on PU-coated ePTFE grafts (Figure  6 c). 
 2.4. Immobilization of Thrombomodulin 
 TPP modifi ed grafts were exposed to recombinant TM 
expressing either a single C-terminal azide moiety (TM-N 3 ) or © 2011 WILEY-VCH Verlag GAdv. Funct. Mater. 2011, 21, 4736–4743
 Figure  5 .  Survey and high resolution X-ray photoelectron spectroscopy 
ePTFE graft lumen following (a) surface coating with PU, (b) subsequen
Corresponding high resolution C 1 s XPS were performed on the ePTFE gra
modifi cation, and (f) NH 2 –PEG 11 –TPP linker immobilization. a native methionine (TM-methionine). Following a phosphate 
buffered saline (PBS, pH 7.4) rinse for 24 h, the capacity to acti-
vate PC was assessed in vitro. Grafts reacted with TM-N 3 afforded 
a 30-fold increase in their capacity to activate aPC as com-
pared to grafts incubated with TM-methionine ( ∼ 0.4 vs  ∼ 12 ng 
aPC cm  − 2 min  − 1 , p  < 0.01;  Figure  7 a ). The density of cova-
lently bound TM was measured using a horseradish peroxidase 
(HRP) conjugated antibody that recognizes the human TM 
EGF  5,6 domain. Surface density of TM-N 3 was  ∼ 170 fmol/cm 2 
after subtracting background binding of antibody to unmodifi ed 
PU (Figure 7b). [47]  The aPC generating capacity reported herein 
is greater than that previously reported for random immobiliza-
tion strategies. [34,37]  Since the minimum aPC fl ux required to mbH & Co. KGaA, Weinheim 4739wileyonlinelibrary.com
(XPS) of PU modifi ed ePTFE grafts. Survey XPS were performed on the 
t isocyanate modifi cation, and (c) NH 2 –PEG 11 –TPP linker immobilization. 
ft lumen following (d) surface coating with PU, (e) subsequent isocyanate 
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 Figure  6 .  Feasibility of immobilizing azide probes by Staudinger Ligation on polyurethane 
fi lms. (a) Visual confi rmation of solvent cast PU fi lms derivatized with TPP and reacted with 
either (left) rhodamine B or (right) rhodamine azide. (b) Solvent cast thin PU fi lms activated 
with TPP anchor groups were reacted with either rhodamine B or rhodamine azide and analyzed 
by UV-Vis spectroscopy. (c) En face examination of TPP modifi ed grafts following reaction with 
(i) rhodamine B or (ii) rhodamine azide and rinsing with methanol. 
 Table  1.  Elemental analysis of modifi ed ePTFE grafts by XPS. 
 Survey XPS High Resolution C 1 s XPS
Substrate C [%] O [%] N [%] C/O Ratio C–C [%] C–O [%] O– C = O N– C = O [%]
PU a) 81 17 1.6 4.8 65 13 1.1
PU–NCO b) 86 13 0.70 6.6 74 6.0 9.2
PU–TPP c) 70 24 4.6 2.9 50 45 2.8
 a)Bare polyurethane (PU);  b) isocyanate activated PU;  c) PU–NCO reacted with NH 2 –PEG 11 –TPP linker. inhibit thrombosis has not been established, predicting in vivo 
performance is not feasible. 
 Biostability was assessed by subjecting TM-modifi ed grafts 
to PBS at a shear rate of 500 s  − 1 and 37  ° C for 24 h, as well © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Wein0 wileyonlinelibrary.com
 Figure  7 .  Measurement of thrombomodulin (TM) cofactor activity to generate aPC, TM surface 
ePTFE grafts. (a) Catalytic activity of TPP modifi ed ePTFE grafts reacted with recombinant TM 
containing its native C-terminal methionine. (b) Surface density of TM on grafts was quantifi ed 
binding of antibody to bare PU coated ePTFE. (c) Graft activity measured as a percentage of
500 s  − 1 at 37  ° C and subsequent 2-week incubation in PBS at 37  ° C. Data represents mean  ± stan
(p  < 0.01) versus control is denoted by a double asterisk. as to an additional 2 week period in PBS at 
37  ° C. Catalytic activity remained nearly con-
stant indicating that covalently immobilized 
TM-N 3 was unaffected by short-term exposure 
to arterial shear, as well as extended incuba-
tion under physiologically relevant pH and 
temperature conditions (Figure  7 c). Notably, 
random amine-crosslinking techniques used 
to immobilize TM on ePTFE resulted in a 
50% reduction in surface activity following 
exposure to mechanical shear for 7 hours at 
37  ° C. [ 27 ] Others have reported a  ∼ 30% reduc-
tion in activity when TM modifi ed surfaces 
were subjected to static incubation in PBS at 
37  ° C for 4 weeks. [ 29 ] 
 2.5. In Vivo Performance of ePTFE Grafts 
Modifi ed with Thrombomodulin 
 The ex vivo femoral arteriovenous shunt 
model provides a means to assess the throm-bogenicity of blood contacting materials under dynamic arterial 
fl ow conditions, particularly when implanted in sub-human 
primates, such as the baboon, whose hemostatic system closely 
resembles that of man. [ 48–51 ] Platelet binding to PU coated heim Adv. Funct. Mater. 2011, 21, 4736–4743
density, and stability of immobilized TM on modifi ed 
expressing a C-terminal azide moiety (TM-N 3 ) or TM 
using a TM antibody and compared with background 
 initial levels following 24 h of mechanical shear at 
dard deviation for n  ≥ 3 samples. Statistical difference 
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 Figure  8 .  Real time platelet deposition on modifi ed ePTFE grafts in the 
absence of an upstream thrombus source in the baboon shunt model. 
(a) Shunt confi guration for testing thrombogenicity of 4 mm i.d. tubular 
materials. (b) Representative photo of a 7 cm length bare PU coated 
ePTFE graft split in half lengthwise following 1 h perfusion at 100 mL/min; 
Arrow points in direction of blood fl ow. (c) Comparison of platelet deposi-
tion on bare PU coated 4 mm i.d. ePTFE (ePTFE  + PU) with plain 4 mm 
i.d. Dacron grafts. Each data point represents mean  ± standard deviation 
for n  ≥ 3 samples. Statistical difference (p  < 0.01) is denoted by double 
asterisk. PTFE grafts (4 mm i.d.) was assessed using an arteriovenous 
perfusion chamber and compared to responses observed to 
unmodifi ed Dacron grafts ( Figure  8 ). [ 49 , 52 ] Cumulative platelet 
deposition on PU coated ePTFE was substantially lower than 
on Dacron grafts (0.0082 vs 1.5 billion/cm 2 ). Since the level 
of platelet deposition on PU coated ePTFE grafts is too low to 
gauge the therapeutic effi cacy of immobilized TM, we explored 
thrombus growth in a perfusion system in which a test graft was 
interposed between a collagen coated ePTFE graft, as a throm-
bogenic source, and a distal expansion chamber ( Figure  9 ). [ 48 , 49 ] 
TM modifi ed ePTFE grafts reduced platelet deposition in the 
distal expansion chamber by nearly 50% when compared to 
unmodifi ed PU coated grafts (n  = 4, p  < 0.05). Since thrombin 
is an important physiological agonist for platelet activation, [ 6 ] 
the measured reduction of platelet deposition in the distal 
expansion chamber suggests that substantial levels of aPC are 
generated from the TM modifi ed surface. In addition to atten-
uating thrombosis, local generation of aPC may infl uence the © 2011 WILEY-VCH Verlag GmAdv. Funct. Mater. 2011, 21, 4736–4743healing characteristics of implanted grafts, as late prosthetic 
graft failure has been attributed to progressive intimal hyper-
plasia, a process exacerbated by thrombin and platelet derived 
pro-infl ammatory factors. [ 7 , 53 ] 
 3. Conclusions 
 We have presented a biomimetic surface engineering approach 
that combines molecular engineering and orthogonal chem-
istry strategies to site-specifi cally functionalize clinical vascular 
prostheses with recombinant human TM that exhibit biocata-
lytic activity and biostability in vitro. Moreover, we have devised 
and tested a robust, clinically relevant in vivo model of vas-
cular graft thrombosis in non-human primates that facilitated 
evaluation of the therapeutic function of bioactive TM surface 
assemblies. The data presented herein indicate that a biologi-
cally active TM surface assembly reduces the thrombogenic 
properties of blood contacting surfaces despite the presence 
of an upstream thrombin generating stimulus. The modular 
nature of heterobifunctional linker design, combined with 
recent advances in chemoselective techniques to modify pep-
tides and proteins, [ 54 , 55 ] will undoubtedly expand the utility of 
bioenzyme surface assemblies to a range of clinically important 
host-material interfaces. 
 4. Experimental Section
 Reagents : All reagents were purchased from Sigma-Aldrich, St Louis 
and used without further purifi cation unless otherwise noted. Expression 
and purifi cation of recombinant TM-methionine and TM-N 3 are detailed 
elsewhere  [38] . 
 Synthesis of NH 2 –PEG 11 –TPP : NH 2 –PEG 11 –TPP was synthesized 
by reaction of  O- (2-aminoethyl)- O′ -[2-(Boc-amino)ethyl]decaethylene 
glycol with a pentafl uorophenyl ester of TPP [46] in CH 2 Cl 2 and 
3 equiv 2,6-lutidine at 25  ° C for 12 h, followed by removal of Boc using 
CF 3 COOH and purifi cation by column chromatography.  1 H NMR 
(400 MHz, CDCl 3 ):  δ 8.10 (dd, 1H, J  = 3.6, 8), 7.83 (dd, 1H, J  = 1.6, 
8.4), 7.39-7.28 (m, 11H), 6.81 (m, 1H), 3.80 (brs, 2H), 3.76 (s, 3H), 
3.70-3.49 (m, 46H), 2.97 (t, 2H, J  = 5.2); HRMS (ESI,  m/z ): [M + H]  +  calcd 
for C 45 H 68 N 2 O 14 P, 891.4408; found, 891.4396. 
 Modifi cation of ePTFE Grafts : 5% w/v Elasthane 80A (Polymer Tech, 
Berkeley) in  N,N -dimethylformamide (DMF) was extravasated through 
4 mm i.d. ePTFE thin wall vascular grafts (Bard, Tempe) and dried under 
vacuum at 60  ° C for 20 min. Additional PU was deposited in multiple 
fl ow-through/drying cycles over the base layer, and dried overnight under 
vacuum at 60  ° C. PU coated grafts were inserted into tubular reactors as 
depicted in Figure  4 and rotated at 500 rpm for surface reactions. Grafts 
were fi rst reacted with HDI (16% v/v) and TEA (4% v/v) in toluene 
at 50  ° C for 1 h and rinsed in toluene for 6 h. Isocyanate activated 
grafts were reacted with NH 2 –PEG 11 –TPP linker (10 mg/mL) and TEA 
(1% v/v) in toluene at 40 ° C overnight, rinsed with toluene for 6 h, 
and dried under vacuum at 25  ° C overnight. TPP activated grafts 
were reacted with 1 mg/mL tetramethylrhodamine-5-carbonyl azide 
(Invitrogen, Carlsbad) in 1:4 tert-butanol/PBS at 37 ° C for 24 h followed 
by rinsing in methanol for 24 h, or reacted with 20  μ M TM-N 3 in PBS at 
37 ° C for 24 h and rinsed with PBS for 24 h. Grafts coated with PU and 
activated with TPP were reacted with rhodamine B or TM-methionine 
as controls. 
 Modifi cation of Polyurethane Films : Thin clear PU fi lms were solvent 
cast by drying 12.5% w/v Elasthane 80A in DMF for 24 h at 60  ° C under 
vacuum. Films were subjected to isocyanate, TPP, and rhodamine 
reactions in a glass vial using identical conditions as graft substrates, bH & Co. KGaA, Weinheim 4741wileyonlinelibrary.com
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 Figure  9 .  The biological function of TM modifi ed ePTFE grafts was evaluated using a three-compartment thrombogenic device inserted into chronic 
arteriovenous shunts in baboons. (a) A 2 cm  × 4 mm inner diameter (i.d.) segment of collagen coated ePTFE serving as a thrombin source was con-
nected upstream of a 7 cm  × 4 mm i.d. segment of test graft, and the therapeutic function of aPC generated  in situ was detected in a 1 cm  × 10 mm i.d. 
distal expansion chamber. Arrow points in direction of blood fl ow. (b) Representative photograph of the entire chamber assembly that tested a 7 cm 
TM modifi ed ePTFE graft split in half lengthwise following perfusion for 1 h at 100 mL/min. Arrow points in direction of blood fl ow. Real-time platelet 
deposition (c) in the upstream collagen coated 4 mm i.d. ePTFE segment; (d) in the thrombus tail developing distal to collagen coated ePTFE; and 
(e) in the 10 mm i.d. expansion chamber distal to TM modifi ed ePTFE grafts (PU  + TM) compared with bare PU coated ePTFE controls. Each data 
point represents mean  ± standard deviation of 4 independent studies. Statistical difference (p  < 0.05) is denoted by single asterisk. and characterized by UV-Vis spectroscopy (Cary 50 Bio UV-visible 
spectrophotometer, Varian). 
 Surface Analysis : An in-lens fi eld-emission SEM (ISI DS-130F Schottky 
Field Emission SEM) operated at 10 kV was used to examine the graft 
luminal surface. Light microscopy images of serial thin sections of 
modifi ed grafts were used to determine PU thickness. ATR-IR spectra 
were acquired using a FTS-4000 FT-IR spectrometer (Bio-Rad, Hercules) 
equipped with a wide-band MCT detector, collected with 100 scans 
at 2 cm  − 1 resolution. XPS data were recorded on an Axis Ultra X-ray 
photoelectron spectrometer (Kratos Analyticals, UK) equipped with a 
monochromatized Al K α X-ray source. 
 TM Graft Cofactor Activity Assay : A 4 mm graft segment was incubated 
in 200  μ L of 0.2  μ M human protein C (Calbiochem, Gibbstown), 
5 mM calcium chloride, and 2 nM human  α -thrombin (Haematologic 
Technologies, Essex Junction) in Tris buffer (20 mM Tris, 100 mM NaCl, 
pH 7.5) with 0.1% bovine serum albumin (BSA) at 37  ° C for 1 h, and 
quenched with 2 IU/mL human anti-thrombin III (American Diagnostica, 
Stamford) for 5 min. The generation of aPC was quantifi ed using 
0.2 mM of an enzymatically digestible chromogenic substrate, 
Spectrozyme PCa (American Diagnostica). TM activity was assayed after 
grafts were exposed for 24 h to PBS at 37  ° C and 500 s  − 1 shear, as well 
as after incubation in PBS with 0.02% sodium azide at 37  ° C over a two 
week period. 
 Determination of TM Surface Density : All assay reactions were run in 
a 96-well plate, per manufacturer’s instructions (American Diagnostica, 
Stamford). Moles of EGF 5-6 domains bound to test grafts were calculated 
by a standard curve generated by ELISA using known concentrations of 
TM. At the end of each assay, graft segments were fl attened between 
glass slides and scanned at 600 dpi using a HP ScanJet 5370C scanner © 2011 WILEY-VCH Verlag G42 wileyonlinelibrary.comand the reactive area of each test sample was measured using ImageJ 
software. 
 In Vivo Baboon Arteriovenous Shunt Model : A chronic exteriorized 
arteriovenous shunt was implanted in male baboons, as previously 
described. [ 49 , 52 ] All studies were approved by the Institutional Animal 
Care and Use Committee at Oregon Health and Science University. 
Mean blood fl ow rate through the shunt was measured continuously 
using a Doppler ultrasonic fl ow meter and held constant by an external 
screw clamp at 100 mL/min. Autologous platelets were radiolabeled 
one day prior to shunt study with Indium-111 oxine and re-injected into 
the baboon. Platelet deposition in the individual compartments of the 
shunt assembly was measured over a 60-minute perfusion period using 
a high sensitivity 99Tc collimator and scintillation camera (GE 400T, 
General Electric) imaging of the 172 keV  111 In g photon peak at 5-min 
intervals. [ 52 ] 
 Statistical Analysis : Two-tailed student’s t-test assuming unequal 
variances was used to test for statistical signifi cance between the means 
of two groups. 
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